drugset
Drugs / DNL151
last change May 2026 re-read 3 minutes ago

DNL151

Developed for
Parkinson disease
Investigated by
Biogen · Denali Therapeutics Inc.

Trials 2

today NCT04056689 · Ph 1 NCT04557800 · Ph 1
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04056689 Jul 2019 → Dec 2020 Parkinson disease Biogen Completed No outcome recorded
Phase 1 NCT04557800 Nov 2017 → Feb 2021 — Denali Therapeutics Inc. Completed No outcome recorded

Press releases naming this drug 5 releases

DateIssuerRelease
2026-05-21 Denali Therapeutics Inc. Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease denalitherapeutics.com ↗
2026-05-21 Biogen Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease biogen.com ↗
2021-05-01 Denali Therapeutics Inc. Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson’s Disease denalitherapeutics.com ↗
2020-08-06 Denali Therapeutics Inc. Denali Therapeutics Announces Decision to Advance DNL151 into Late Stage Clinical Studies in Parkinson’s Patients denalitherapeutics.com ↗
2019-09-04 Denali Therapeutics Inc. Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease and Launch of Its Engage Parkinson’s Website denalitherapeutics.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as DNL151 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04557800 ↗
1

NCT04056689 ↗
Route Oral “multiple oral doses of DNL151” NCT04056689 ↗